Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CLNN

CLNN - Clene Inc. Stock Price, Fair Value and News

$4.91-0.28 (-5.39%)
Market Closed

Price Targets

Target 1Y

$4.25

Target 3M

$4.78

Target 6M

$4.51

CLNN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CLNN Price Action

Last 7 days

-5.4%

Last 30 days

-16.6%

Last 90 days

-50.9%

Trailing 12 Months

4.0%

CLNN RSI Chart

CLNN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CLNN Valuation

Market Cap

50.7M

Price/Earnings (Trailing)

-1.66

Price/Sales (Trailing)

237.1

EV/EBITDA

-1.55

Price/Free Cashflow

-2.74

CLNN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.25

Target 3M

$4.78

Target 6M

$4.51

CLNN Fundamentals

CLNN Revenue

Revenue (TTM)

214.0K

Rev. Growth (Yr)

-82.76%

Rev. Growth (Qtr)

-44.44%

CLNN Earnings

Earnings (TTM)

-30.5M

Earnings Growth (Yr)

-9.9%

Earnings Growth (Qtr)

-18.3%

CLNN Profitability

Operating Margin

82.24%

EBT Margin

-14250.47%

Return on Equity

246.79%

Return on Assets

-136.69%

Free Cashflow Yield

-36.48%

CLNN Investor Care

Shares Dilution (1Y)

29.50%

CLNN Alerts

  • 1 major insider buys and 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025350.0K286.0K214.0K0
2024620.0K442.0K421.0K342.0K
2023550.0K784.0K718.0K654.0K
2022540.0K374.0K438.0K473.0K
2021349.0K541.0K553.0K723.0K
2020000206.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Clene Inc.

CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
 CEO
 WEBSITEhttps://clene.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES75

Clene Inc. Frequently Asked Questions

CLNN is the stock ticker symbol of Clene Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Clene Inc. is 50.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CLNN's fair value in chart for subscribers.

The fair value guage provides a quick view whether CLNN is over valued or under valued. Whether Clene Inc. is cheap or expensive depends on the assumptions which impact Clene Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLNN.

As of Wed Jan 28 2026, CLNN's PE ratio (Price to Earnings) is -1.66 and Price to Sales (PS) ratio is 237.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLNN PE ratio will change depending on the future growth rate expectations of investors.